Skip to content
10-Q

Quarterly Report

Vaccinex, Inc. VCNX

0000950170-24-060603

← back to feed
Filed
May 15, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 10, 2024 1.58M sh
Shares Diluted Q1 2024 · Mar 31, 2024 1.33M sh
Shares Diluted restated Q1 2024 · Mar 31, 2023 237.53K sh
Capex Q1 2024 · Mar 31, 2024 $0
Capex Q1 2024 · Mar 31, 2023 $49K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$4.63M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$5.04M
Long Term Debt Q1 2024 · Mar 31, 2024 $6K
Long Term Debt Q1 2024 · Dec 31, 2023 $26K
Short Term Debt Q1 2024 · Mar 31, 2024 $76K
Short Term Debt Q1 2024 · Dec 31, 2023 $75K
Cash And Equivalents Q1 2024 · Mar 31, 2024 $2.97M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $1.54M
Current Liabilities Q1 2024 · Mar 31, 2024 $4.71M
Current Liabilities Q1 2024 · Dec 31, 2023 $5.92M
Total Liabilities Q1 2024 · Mar 31, 2024 $4.71M
Total Liabilities Q1 2024 · Dec 31, 2023 $5.94M
Current Assets Q1 2024 · Mar 31, 2024 $7.15M
Current Assets Q1 2024 · Dec 31, 2023 $3.35M
Total Assets Q1 2024 · Mar 31, 2024 $7.37M
Total Assets Q1 2024 · Dec 31, 2023 $3.63M
Eps Diluted Q1 2024 · Mar 31, 2024 −$2.94
Eps Diluted restated Q1 2024 · Mar 31, 2023 −$20.89
Eps Basic Q1 2024 · Mar 31, 2024 −$2.94
Eps Basic restated Q1 2024 · Mar 31, 2023 −$20.89
Sga Expense Q1 2024 · Mar 31, 2024 $1.8M
Sga Expense Q1 2024 · Mar 31, 2023 $1.72M
Rd Expense Q1 2024 · Mar 31, 2024 $3.38M
Rd Expense Q1 2024 · Mar 31, 2023 $3.81M
Net Income Q1 2024 · Mar 31, 2024 −$3.9M
Net Income Q1 2024 · Mar 31, 2023 −$4.96M
Operating Income Q1 2024 · Mar 31, 2024 −$5.07M
Operating Income Q1 2024 · Mar 31, 2023 −$4.99M
Revenue Q1 2024 · Mar 31, 2024 $104K
Revenue Q1 2024 · Mar 31, 2023 $550K